MedCap AB (CHIX:MCAPS) Tariff Resilience Score: 0/10 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:MCAPS MedCap AB CHIX:MCAPS
93 GF Score
Price kr555.00
GF Value kr596.05
Valuation Fairly Valued
View Full Analysis

What is MedCap AB Tariff Resilience Score?

MedCap AB has the Tariff Resilience Score of 0, which implies that the company might have .

MedCap AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes MedCap AB might have .


MedCap AB  (CHIX:MCAPs) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

MedCap AB Tariff Resilience Score Related Terms

CHIX:MCAPS
93GF Score
MedCap AB CHIX:MCAPS
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MedCap AB (CHIX:MCAPS) Overvalued in 2026?

Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued. The current stock price of kr555.00 is trading 6.9% below its estimated GF Value™ of kr596.05. GuruFocus considers MedCap AB to be Fairly Valued.

Key valuation signals for CHIX:MCAPS:

  • Tariff Resilience Score: 0
  • GF Value™: kr596.05 vs. price of kr555.00 (6.9% below fair value)
  • GF Score™: 93/100

No single metric tells the full story. See the CHIX:MCAPS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MedCap AB Business Description

Other Exchanges MCAP:Sweden61MA:Germany
Address Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
93GF Score

Get the complete analysis for CHIX:MCAPS

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr555.00
Price
kr596.05
GF Value